Clinical trials · Boston, MA
Refractory Non-Hodgkin Lymphoma clinical trials in Boston
We’re tracking 15 recruiting refractory non-hodgkin lymphoma studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT06026319RecruitingPhase 1
CAR T cells targeting CD79b and CD19 for non-Hodgkin lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
Boston, MassachusettsAges 18 years+ - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Boston, MassachusettsAges 13 years+ - NCT05607420RecruitingPhase 1/Phase 2
Testing a new cell therapy for relapsed lymphoma with CD20/CD22
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Boston, MassachusettsAges 18–80 - NCT06137144RecruitingPhase 1/Phase 2
Study of AZD3470 for blood cancers alone or with other drugs
This trial tests a new drug called AZD3470, given alone or with other cancer treatments, for people with certain types of lymphoma (Hodgkin's lymphoma or T-cell lymphoma). It aims to see if the drug is safe and effective for patients who have already tried other treatments.
Boston, MassachusettsAges 12 years+ - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Boston, MassachusettsAges 6 months–30 years - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Boston, MassachusettsAges 18 years+ - NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests if the drug emapalumab can help prevent toxic side effects often caused by CAR-T cell therapy. It is for adults with certain types of large B-cell lymphoma that have not responded to or returned after initial treatment.
Boston, MassachusettsAges 18 years+ - NCT06563596RecruitingPhase 2
Study of epcoritamab, zanubrutinib, and rituximab for relapsed lymphoma
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Boston, MassachusettsAges 1–30 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Boston, MassachusettsAges 1–21 - NCT04906096RecruitingPhase 2
Paxalisib for repeat or resistant brain lymphoma
This Phase 2 study tests paxalisib to shrink or control primary CNS lymphoma that has come back or did not respond to prior treatment. It may help by blocking specific cell-growth signals that can drive this lymphoma.
Boston, MassachusettsAges 18 years+ - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Boston, MassachusettsAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Worcester, MassachusettsAges 18 years+ - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Providence, Rhode IslandAges 18 years+ - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Providence, Rhode IslandAges 18 years+
Hear when a new Refractory Non-Hodgkin Lymphoma trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Refractory Non-Hodgkin Lymphoma trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting refractory non-hodgkin lymphoma studies listed above.
- Dana-Farber Cancer Institute · 8 studies
- Massachusetts General Hospital · 3 studies
- Boston Medical Center
- Brigham and Women's Hospital
- Brown University
- Research Site
- Rhode Island Hospital
- University of Massachusetts Chan Medical School
What taking part in a refractory non-hodgkin lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting refractory non-hodgkin lymphoma studies in Massachusetts.
Common questions
- Are there refractory non-hodgkin lymphoma clinical trials near Boston?
- Yes. We're currently tracking 15 recruiting refractory non-hodgkin lymphoma studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory non-hodgkin lymphoma study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory non-hodgkin lymphoma studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.